Results Of A Phase Ib Study Of Regorafenib (Reg) 80 Mg/Day Plus Pembrolizumab (Pembro) For First-Line Treatment Of Advanced Hepatocellular Carcinoma (Hcc).

Richard D. Kim,William P. Harris,Max W. Sung,Dirk Thomas Waldschmidt,Roniel Cabrera,Udo Mueller,Flavia Menezes, Tatiane Ishida,Peter R. Galle,Anthony B. El-Khoueiry

JOURNAL OF CLINICAL ONCOLOGY（2021）

引用 5|浏览8

暂无评分

摘要

323Background: In a phase Ib study, REG 120 mg/day plus PEMBRO for first-line treatment of advanced HCC showed no unexpected safety signals and encouraging anti-tumor activity. At the maximum toler...

查看译文

AI 理解论文

溯源树

样例

生成溯源树，研究论文发展脉络

Chat Paper

正在生成论文摘要